Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-16T10:45:48.311Z Has data issue: false hasContentIssue false
  • English
  • Français

Ten-year-old boy with congenital long QT syndrome type 2 (LQTS2) and life-threatening electrical storm: a case report of successful treatment with mexiletine

Published online by Cambridge University Press:  30 March 2022

Moa Wåström Open the ORCID record for Moa Wåström [Opens in a new window]  and
Jean-Pierre Pfammatter
Moa Wåström*
Affiliation:
Department of Pediatric Cardiology, University Children’s Hospital Zurich, Zurich, Switzerland
Jean-Pierre Pfammatter
Affiliation:
Department of Pediatric Cardiology, University Children’s Hospital Bern, Bern, Switzerland
*
Author for correspondence: M. Wåström, MD, Department of Pediatric Cardiology, University Children’s Hospital Zurich – Eleonorenstiftung, Steinwiesenstrasse 75, CH-8032, Zürich, Switzerland. Tel: +41 78 230 07 08. E-mail: moa.wastroem@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

We present a case of a boy with long QT syndrome type 2, who was admitted after an out of hospital cardiac arrest due to ventricular fibrillation. Subsequently, all treatments – intravenous magnesium, optimisation of electrolytes, an isoproterenol infusion – failed to terminate his electrical storm. As a last option before left-sided cardiac sympathetic denervation, mexiletine was started and the electrical storm resolved completely.

Keywords

Long QT syndrome type 2electrical stormmexiletine
Type
Brief Report
Information
Cardiology in the Young , Volume 32 , Issue 11 , November 2022 , pp. 1871 - 1872
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Skinner, JR, Crawford, J, Smith, W, et al. Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm 2011; 8: 412–419.CrossRefGoogle ScholarPubMed
Tester, DJ, Medeiros-Domingo, A, Will, ML, Haglund, CM, Ackerman, MJ. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012; 87: 524–539.CrossRefGoogle ScholarPubMed
Suarez, K, Mack, R, Hardegree, EL, Chiles, C, Banchs, JE, Gonzalez, MD. Isoproterenol suppresses recurrent torsades de pointes in a patient with long QT syndrome type 2. HeartRhythm Case Rep 2018; 4: 576–579.CrossRefGoogle Scholar
Mazzanti, A, Maragna, R, Faragli, A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol 2016; 67: 1053–1058.CrossRefGoogle ScholarPubMed
Funasako, M, Aiba, T, Ishibashi, K, et al. Pronounced shortening of QT interval with mexiletine infusion test in patients with type 3 congenital long QT syndrome. Circ J 2016; 80: 340–345.CrossRefGoogle ScholarPubMed
Bos, JM, Crotti, L, Rohatgi, RK, et al. Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome. Circ Arrhythm Electrophysiol 2019; 12: e007280.CrossRefGoogle Scholar
Priori, SG, Wilde, AA, Horie, M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013; 10: 1932–1963.CrossRefGoogle ScholarPubMed